Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$0.46 - $0.76 $13,760 - $22,735
-29,915 Reduced 64.17%
16,700 $8,000
Q2 2022

Aug 15, 2022

SELL
$0.58 - $1.13 $10,895 - $21,227
-18,785 Reduced 28.72%
46,615 $27,000
Q1 2022

May 16, 2022

BUY
$0.73 - $1.81 $9,490 - $23,530
13,000 Added 24.81%
65,400 $66,000
Q4 2021

Feb 14, 2022

SELL
$1.66 - $2.64 $45,816 - $72,864
-27,600 Reduced 34.5%
52,400 $87,000
Q3 2021

Nov 15, 2021

SELL
$2.58 - $3.36 $5,160 - $6,720
-2,000 Reduced 2.44%
80,000 $215,000
Q2 2021

Aug 16, 2021

BUY
$2.7 - $3.81 $6,210 - $8,763
2,300 Added 2.89%
82,000 $272,000
Q1 2021

May 17, 2021

BUY
$3.02 - $5.16 $153,718 - $262,644
50,900 Added 176.74%
79,700 $265,000
Q4 2020

Feb 12, 2021

BUY
$2.66 - $4.18 $76,608 - $120,383
28,800 New
28,800 $103,000

Others Institutions Holding MBIO

About MUSTANG BIO, INC.


  • Ticker MBIO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 105,222,000
  • Market Cap $46.3M
  • Description
  • Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (...
More about MBIO
Track This Portfolio

Track Ameriprise Financial Inc Portfolio

Follow Ameriprise Financial Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ameriprise Financial Inc with notifications on news.